1002309-19-4

Basic information

• Product Name: 2-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
• Synonyms: 2-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
• CAS NO: 1002309-19-4
• Molecular Formula: C15H20BNO3
• Molecular Weight: 273.1352
• Mol File: 1002309-19-4.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(1002309-19-4)
• EPA Substance Registry System: 2-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(1002309-19-4)

Safety Data

• Hazardous Substances Data: 1002309-19-4(Hazardous Substances Data)

Upstream product

• 78471-43-9 methyl 4-bromo-2-(bromomethyl)benzoate 
• 868066-91-5 5-bromo-2-methyl-1,3-dihydroisoindol-1-one 
• 73183-34-3 bis(pinacol)diborane 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 

Downstream Products

• 1190875-38-7 (2-methyl-1-oxoisoindolin-5-yl)boronic acid 
• 1567838-15-6 2,4-difluoro-N-(5-(2-(2-methyl-1-oxoisoindolin-5-yl)thiazol-5-yl)pyridin-3-yl)benzenesulphonamide 

Relevant articles and documents

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

BIPYRIDYL COMPOUND

There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound. There is provided a bipyridyl compound represented by a general f

IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS

The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.